Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
3(27%)
Results Posted
120%(6 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_2
6
55%
Ph phase_3
5
45%

Phase Distribution

0

Early Stage

6

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Recruiting2
Terminated2
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (54.5%)
Phase 35 (45.5%)

Trials by Status

recruiting218%
unknown19%
terminated218%
active_not_recruiting19%
completed545%

Recent Activity

3 active trials
Showing 5 of 11
recruitingphase_2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

NCT06942442
recruitingphase_3

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475
terminatedphase_2

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

NCT04488003
completedphase_2

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

NCT03127215
completedphase_3

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT03262935
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06942442Phase 2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Recruiting
NCT05948475Phase 3

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
NCT04488003Phase 2

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Terminated
NCT03127215Phase 2

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed
NCT03262935Phase 3

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
NCT01905592Phase 3

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Terminated
NCT04398914Phase 2

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active Not Recruiting
NCT03329690Phase 2

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Completed
NCT00388726Phase 3

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
NCT01313689Phase 3

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Completed
NCT02353988Phase 2

AR-inhibitor Bicalutamide in Treating Patients With TNBC

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11